86-21-64556180

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
Resources
- Downloadable
- Image gallery
FAQs
Contact Us

Home
Products
Intermediates

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
- DPP-4
- SGLT-1
- SGLT-2
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

Intermediates

CPDD1846
CAS: 1394003-86-1,IPI-549 Intermediate 1
CPDD1845
CPDD2013
CPDD1040
CPDD1035
CAS:1708974-56-4,FGF401 Intermediate A9
CPDD1843
CAS:Free1217651-75-6,MSC2530818 Intermediate
CPDD1840
CPDD0277
ND-630 Intermediate,CAS1434652-66-0
CPDD2020
CPDD2021
CPDD2022
CPDD2023
CPDD2024
CPDD1623
CPDD2026
CPDD1624
CPD2027
CPDD2017
CPD2028
CPDD2018

<< < Previous 2 3 4 5 6 7 Next > >> Page 6 / 7

Contact Us

3rd Floor, Building 4, 3918 Daye Road, Fengxian District, Shanghai
86-21-64556180
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...
ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...
AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

© Copyright - 2015-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !